1
|
Stark A, Yan X\, Stapp R, Raghunathan A, Kirchner L, Griggs J, Newman LA, Dick AW, Chitale D. Ductal carcinoma in situ (DCIS) of the breast: Race- and treatment-adjusted specific disease-free probability. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
186 Background: Findings of DCIS outcome between African-American (AA) and White-American (WA) women are inconclusive. Methods: We conducted a retrospective longitudinal study with the objective of comparing the risk of any second breast cancer after the first primary DCIS, adjusting for pathologic prognostic indicators, treatment, age, and the established epidemiologic risk factors. Women were diagnosed and treated in one institution between 1990-1999. Diagnostic slides were reviewed and prognostic indicators documented; demographic, clinical and method of detection, screening mammography vs. palpation, were collected from medical records. We applied Accelerated Failure Time Modeling (AFTM) to determine the variables that were best associated with the risk of a second cancer. Results: 335 women, 29.6% (n=100) AA with mean age of 60 (±13) and 70.4% (n=235) WA with mean age of 57 (±12.4), contributed to this study. Distributions of some of the prognostic indicators and final treatment are presented. (Table) During the 10 years of follow-up 12.0% (n=12) of AA and 3.0% (n=7) WA experienced second cancer in ipsilateral breasts; 5.0% (n=5) of AA and 3.8% (n=9) WA in their contralateral breasts and 2 women, 1 AA and 1 WA, in both breasts. Results from the AFTM yielded race as the only variable associated with the risk of a second cancer but only in ipsilateral breasts (HR= 4.11, 95% CI=1.6-10.5 p=0.003). Conclusions: No difference in the risk of a second cancer in contralateral breast between AA and WA women support the notion of equal access and equal treatment in comparable treatment outcome. Reasons for increased risk of a second cancer in ipsilateral breast in AA women are being evaluated. [Table: see text]
Collapse
Affiliation(s)
- A. Stark
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| | - X. \(. Yan
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| | - R. Stapp
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| | - A. Raghunathan
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| | - L. Kirchner
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| | - J. Griggs
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| | - L. A. Newman
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| | - A. W. Dick
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| | - D. Chitale
- Geisinger Health System, Danville, PA; Department of Pathology, Henry Ford Health System, Detroit, MI; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; RAND Corporation, Pittsburgh, PA
| |
Collapse
|